...Matthew Walsh as CFO and Rachel Stahler as chief information officer of its planned spinout Organon...
...to complete the spin out of its women’s health business, legacy brands and biosimilars into Organon...

...and CSO of pain company Kadmus Pharmaceuticals Inc. , which sold its key assets to Organon...

...its 2009 acquisition of Schering-Plough Corp. Schering-Plough gained the compound through its 2007 acquisition of Organon...

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon...

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon...

...sequence and expression database and LifeSeq GeneAlbum reagent set in exchange for annual access fees. Organon...
...collaboration. INCY is eligible to receive royalties. Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. NV Organon...

...for milestones and royalties. Organon has all rights to develop and commercialize the humanized antibody. Organon...

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon...

...Merck's Organon N.V. subsidiary proposed to restructure and reduce headcount of R&D at Dutch sites Oss...
...reduce headcount of R&D at Dutch sites Oss and Schaijk by 551 (53%) to 479. Organon...

...In an update last week, the pharma said it has been unable to sell its MSD-Organon...
...Merck said only the R&D portion of the facilities would be closed or divested. Of MSD-Organon's...
...internally, which could include the creation of a small R&D center of excellence at the Organon...